Drug Profile
Zabedosertib - Bayer
Alternative Names: BAY 1834845; IRAK-4 inhibitor - BayerLatest Information Update: 15 Mar 2024
Price :
$50
*
At a glance
- Originator Bayer
- Class Amides; Anti-inflammatories; Antipsoriatics; Antirheumatics; Fluorinated hydrocarbons; Indazoles; Organic sulfur compounds; Pyridines; Skin disorder therapies; Small molecules
- Mechanism of Action Interleukin-1 receptor-associated kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Atopic dermatitis
- Phase I Unspecified
- No development reported Pelvic inflammatory disorders; Psoriasis; Rheumatoid arthritis
Most Recent Events
- 03 Jan 2024 Bayer completes phase-II Damask trial in Atopic dermatitis (In adults, In the elderly) in United Kingdom, Italy, Poland, Germany, France, Czech Republic and USA (PO) (NCT05656911)
- 28 Aug 2023 No recent reports of development identified for phase-I development in Psoriasis in Germany (PO)
- 28 Aug 2023 No recent reports of development identified for phase-I development in Rheumatoid-arthritis in Germany (PO)